Display options
Cite
Catalano MG, Pugliese M, Gallo M, et al. Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial. Int J Endocrinol. 2016;2016:2930414doi: 10.1155/2016/2930414.
Catalano, M. G., Pugliese, M., Gallo, M., Brignardello, E., Milla, P., Orlandi, F., Limone, P. P., Arvat, E., Boccuzzi, G., & Piovesan, A. (2016). Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial. International journal of endocrinology, 20162930414. https://doi.org/10.1155/2016/2930414
Catalano, Maria Graziella, et al. "Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial." International journal of endocrinology vol. 2016 (2016): 2930414. doi: https://doi.org/10.1155/2016/2930414
Catalano MG, Pugliese M, Gallo M, Brignardello E, Milla P, Orlandi F, Limone PP, Arvat E, Boccuzzi G, Piovesan A. Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial. Int J Endocrinol. 2016;2016:2930414. doi: 10.1155/2016/2930414. Epub 2016 Sep 27. PMID: 27766105; PMCID: PMC5059567.
Copy Download .nbib Format: NLM
Share it on

Int J Endocrinol. 2016;2016:2930414. doi: 10.1155/2016/2930414. Epub 2016 Sep 27.

Valproic Acid, a Histone Deacetylase Inhibitor, in Combination with Paclitaxel for Anaplastic Thyroid Cancer: Results of a Multicenter Randomized Controlled Phase II/III Trial.

International journal of endocrinology

Maria Graziella Catalano, Mariateresa Pugliese, Marco Gallo, Enrico Brignardello, Paola Milla, Fabio Orlandi, Paolo Piero Limone, Emanuela Arvat, Giuseppe Boccuzzi, Alessandro Piovesan

Affiliations

  1. Department of Medical Sciences, University of Turin, Turin, Italy.
  2. Oncological Endocrinology, A.O.U. "Città della Salute e della Scienza di Torino" Hospital, Turin, Italy.
  3. Transition Unit for Childhood Cancer Survivors, A.O.U. "Città della Salute e della Scienza di Torino" Hospital, Turin, Italy.
  4. Department of Drug Science and Technology, University of Turin, Turin, Italy.
  5. Section of Endocrinology, Division of Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy.
  6. Endocrinology, Diabetes, and Metabolism Unit, A.O. Ordine Mauriziano di Torino, "Umberto I" Hospital, Turin, Italy.
  7. Department of Medical Sciences, University of Turin, Turin, Italy; Oncological Endocrinology, A.O.U. "Città della Salute e della Scienza di Torino" Hospital, Turin, Italy.

PMID: 27766105 PMCID: PMC5059567 DOI: 10.1155/2016/2930414

Abstract

Anaplastic thyroid cancer (ATC) has a median survival less than 5 months and, to date, no effective therapy exists. Taxanes have recently been stated as the main drug treatment for ATC, and the histone deacetylase inhibitor valproic acid efficiently potentiates the effects of paclitaxel

References

  1. EMBO J. 2001 Dec 17;20(24):6969-78 - PubMed
  2. PLoS One. 2013 Oct 14;8(10):e77684 - PubMed
  3. Clin Cancer Res. 2006 Sep 15;12(18):5570-7 - PubMed
  4. Cancer. 1987 Nov 15;60(10):2372-5 - PubMed
  5. J Oncol. 2011;2011:542358 - PubMed
  6. Int J Cancer. 2012 Feb 1;130(3):694-704 - PubMed
  7. Radiother Oncol. 2011 Dec;101(3):425-30 - PubMed
  8. J Natl Compr Canc Netw. 2015 Sep;13(9):1140-50 - PubMed
  9. Thyroid. 2010 Jan;20(1):7-14 - PubMed
  10. Thyroid. 2013 May;23(5):600-4 - PubMed
  11. EMBO J. 2003 Mar 3;22(5):1168-79 - PubMed
  12. PLoS One. 2006 Dec 20;1:e98 - PubMed
  13. Clin Oncol (R Coll Radiol). 2010 Aug;22(6):486-97 - PubMed
  14. J Clin Endocrinol Metab. 2009 Jan;94(1):164-70 - PubMed
  15. Nat Rev Cancer. 2004 Apr;4(4):253-65 - PubMed
  16. Clin Ther. 2008 Aug;30(8):1385-407 - PubMed
  17. Blood. 2008 Feb 1;111(3):1060-6 - PubMed
  18. J Clin Endocrinol Metab. 2012 Sep;97(9):3179-84 - PubMed
  19. Anticancer Res. 2008 Jul-Aug;28(4C):2519-27 - PubMed
  20. J Clin Endocrinol Metab. 2012 Jul;97(7):E1150-9 - PubMed
  21. Br J Clin Pharmacol. 2001 Nov;52(5):547-53 - PubMed
  22. Thyroid. 2014 Nov;24(11):1600-6 - PubMed
  23. Thyroid. 2009 Mar;19(3):233-40 - PubMed
  24. Endocr Relat Cancer. 2007 Sep;14(3):839-45 - PubMed
  25. J Clin Oncol. 2007 May 20;25(15):1979-85 - PubMed
  26. J Biol Chem. 2001 Sep 28;276(39):36734-41 - PubMed
  27. Br J Pharmacol. 2006 Oct;149(3):250-60 - PubMed
  28. Surgery. 2001 Dec;130(6):1028-34 - PubMed
  29. Thyroid. 1998 Aug;8(8):715-26 - PubMed
  30. Thyroid. 2013 Jul;23(7):838-46 - PubMed
  31. Jpn J Clin Oncol. 2010 Jun;40(6):596-9 - PubMed
  32. Curr Opin Oncol. 2013 May;25(3):224-8 - PubMed
  33. J Endocrinol. 2006 Nov;191(2):465-72 - PubMed
  34. Pharmacol Ther. 2014 Sep;143(3):323-36 - PubMed
  35. Thyroid. 2012 Nov;22(11):1104-39 - PubMed
  36. Thyroid. 2014 Feb;24(2):232-40 - PubMed
  37. Oncotarget. 2015 Nov 3;6(34):36383-99 - PubMed

Publication Types